Filing Details

Accession Number:
0001144204-17-038358
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-26 16:44:33
Reporting Period:
2017-07-25
Filing Date:
2017-07-26
Accepted Time:
2017-07-26 16:44:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479419 Kala Pharmaceuticals Inc. KALA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315082 Ra Capital Healthcare Fund Lp C/O Ra Capital Management, Llc
20 Park Plaza, Suite 1200
Boston MA 02116
No No No Yes
1346824 Ra Capital Management, Llc 20 Park Plaza, Suite 1200
Boston MA 02116
Yes No No No
1384859 Peter Kolchinsky C/O Ra Capital Management, Llc
20 Park Plaza, Suite 1200
Boston MA 02116
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-25 1,579,903 $0.00 1,579,903 No 4 C Indirect See footnotes
Common Stock Acquisiton 2017-07-25 533,333 $15.00 2,113,236 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2017-07-25 3,819,444 $0.00 733,337 $0.00
Common Stock Series C Preferred Stock Disposition 2017-07-25 4,409,170 $0.00 846,566 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series B Preferred Stock and the Series C Preferred Stock converted into Common Stock on a 5.2083-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. Includes (a) 1,300,057 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P.(the "Fund") and (b) 279,846 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
  3. Includes (a) 427,043 shares of Common Stock held by the Fund and (b) 106,290 held in the Account, in each case acquired in the Issuer's initial public offering.
  4. These securities include 1,727,100 shares held by the Fund and 386,136 shares held in the Account.
  5. Includes (a) 3,143,402 shares of Series B Convertible Preferred Stock that were held by the Fund and (b) 676,042 shares of Series B Convertible Preferred Stock that were held in the Account.
  6. Includes (a) 3,627,688 shares of Series C Convertible Preferred Stock that were held by the Fund and (b) 781,482 shares of Series C Convertible Preferred Stock that were held in the Account.
  7. RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities in reliance on Rule 16a-1(a)(1)(v) and (vii) and disclaim any obligation to file reports under Section 16 other than as directors by deputization. The Adviser and Dr. Kolchinsky have no pecuniary interest in the reported securities held in the Account and disclaim: (A) beneficial ownership thereof for purposes of Rule 16a-1(a)(2) and (B) beneficial ownership of securities held by the Fund, for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.